Erdheim-chester disease

Current Rheumatology Reports

Volumn 16, Issue 4, 2014, Pages

  Haroche, Julien ^a,b   Arnaud, Laurent ^a,b   Cohen Aubart, Fleur ^a,b   Hervier, Baptiste ^a,b   Charlotte, Frédéric ^a,b   Emile, Jean François ^a,c   Amoura, Zahir ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

BRAF; Epidemiology; Erdheim Chester disease; Histiocytosis; Interferon alpha; Langerhans cell histiocytosis; NRAS; Pathophysiology; Treatment; Vemurafenib

Indexed keywords

ALPHA INTERFERON; B RAF KINASE; CD68 ANTIGEN; CLADRIBINE; IMATINIB; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PEGINTERFERON ALPHA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; T6 ANTIGEN; TECHNETIUM 99M; VEMURAFENIB; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ARTICLE; BONE DISEASE; BONE SCINTISCANNING; BRAF GENE; BREAST DISEASE; BREAST INFILTRATION; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DISEASE ACTIVITY; DRUG TOLERANCE; ENDOCRINE DISEASE; ERDHEIM CHESTER DISEASE; FOLLOW UP; HUMAN; INHIBITION KINETICS; LANGERHANS CELL HISTIOCYTOSIS; LOW DRUG DOSE; LUNG DISEASE; MUTATIONAL ANALYSIS; ORBIT DISEASE; PATHOPHYSIOLOGY; PROGNOSIS; RETROORBITAL INFILTRATION; SKIN DISEASE; TH1 CELL; TREATMENT RESPONSE; DRUG ANTAGONISM; GENETICS; MUTATION; RARE DISEASE; REVIEW;

ERDHEIM-CHESTER DISEASE; HUMANS; INDOLES; INTERFERON-ALPHA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RARE DISEASES; SULFONAMIDES;

EID: 84893683315     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-014-0412-0     Document Type: Article

References (60)

1. Chester W. Über lipoidgranulomatose. Virchows Arch Pathol Anat. 1930;279:561-602.
2. Adam Z, Koukalova R, Sprlakova A, et al. Successful treatment of Erdheim-Chester disease by 2-chlorodeoxyadenosine-based chemotherapy. Two case studies and a literature review. Vnitr Lek. 2011;57:576-89.
3. Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol. 2012;24:53-9.
4. Arnaud L, Hervier B, Neel A, et al. CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117:2778-82. This is a major study, with the largest description of ECD series to date, describing the efficacy of interferon alpha, a major independent predictor of survival, and the importance of CNS involvement, a major prognostic factor and an independent predictor of death in ECD.
5. Haroche J, Amoura Z, Dion E, et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore). 2004;83:371-92.
6. Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, et al. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore). 1996;75:157-69.
7. Brower AC, Worsham GF, Dudley AH. Erdheim-Chester disease: a distinct lipoidosis or part of the spectrum of histiocytosis? Radiology. 1984;151:35-8.
8. Tsai JW, Tsou JH, Hung LY, et al. Combined Erdheim-Chester disease and Langerhans cell histiocytosis of skin are both monoclonal: a rare case with human androgen-receptor gene analysis. J Am Acad Dermatol. 2010;63:284-91.
9. Wang KH, Cheng CJ, Hu CH, et al. Coexistence of localized Langerhans cell histiocytosis and cutaneous Rosai-Dorfman disease. Br J Dermatol. 2002;147:770-4.
10. Balink H, Hemmelder MH, de Graaf W, et al. Scintigraphic diagnosis of Erdheim-Chester disease. J Clin Oncol. 2011;29:e470-2.
11. Haroche J, Amoura Z, Wechsler B, et al. Erdheim-Chester disease. Press Med. 2007;36:1663-8.
12. Andre M, Delevaux I, de Fraissinette B, et al. Two enlarged kidneys: a manifestation of Erdheim-Chester disease. Am J Nephrol. 2001;21:315-7.
13. Dion E, Graef C, Haroche J, et al. Imaging of thoracoabdominal involvement in Erdheim-Chester disease. AJR Am J Roentgenol. 2004;183:1253-60.
14. Haroche J, Amoura Z, Trad SG, et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum. 2006;54:3330-6.
15. Jeon IS, Lee SS, Lee MK. Chemotherapy and interferon-alpha treatment of Erdheim-Chester disease. Pediatr Blood Cancer. 2010;55:745-7.
16. Tran TA, Fabre M, Pariente D, et al. Erdheim-Chester disease in childhood: a challenging diagnosis and treatment. J Pediatr Hematol Oncol. 2009;31:782-6.
17. Arnaud L, Malek Z, Archambaud F, et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease. Arthritis Rheum. 2009;60:3128-38.
18. Stenova E, Steno B, Povinec P, et al. FDG-PET in the Erdheim-Chester disease: its diagnostic and follow-up role. Rheumatol Int. 2012;32:675-8.
19. Dion E, Graef C, Miquel A, et al. Bone involvement in Erdheim-Chester disease: imaging findings including periostitis and partial epiphyseal involvement. Radiology. 2006;238:632-9.
20. Serratrice J, Granel B, De Roux C, et al. "Coated aorta": a new sign of Erdheim-Chester disease. J Rheumatol. 2000;27:1550-3.
21. Gupta A, Kelly B, McGuigan JE. Erdheim-Chester disease with prominent pericardial involvement: clinical, radiologic, and histologic findings. Am J Med Sci. 2002;324:96-100.
22. Haroche J, Cluzel P, Toledano D, et al. Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation. 2009;119:e597-8.
23. Fink MG, Levinson DJ, Brown NL, et al. Erdheim-Chester disease. Case report with autopsy findings. Arch Pathol Lab Med. 1991;115:619-23.
24. Loeffler AG, Memoli VA. Myocardial involvement in Erdheim-Chester disease. Arch Pathol Lab Med. 2004;128:682-5.
25. Kenn W, Stabler A, Zachoval R, et al. Erdheim-Chester disease: a case report and literature overview. Eur Radiol. 1999;9:153-8.
26. Alper MG, Zimmerman LE, Piana FG. Orbital manifestations of Erdheim-Chester disease. Trans Am Ophthalmol Soc. 1983;81:64-85.
27. Sheidow TG, Nicolle DA, Heathcote JG. Erdheim-Chester disease: two cases of orbital involvement. Eye (Lond). 2000;14:606-12.
28. Khamseh ME, Mollanai S, Hashemi F, et al. Erdheim-Chester syndrome, presenting as hypogonadotropic hypogonadism and diabetes insipidus. J Endocrinol Invest. 2002;25:727-9.
29. Tritos NA, Weinrib S, Kaye TB. Endocrine manifestations of Erdheim-Chester disease (a distinct form of histiocytosis). J Intern Med. 1998;244:529-35.
30. Haroche J, Amoura Z, Touraine P, et al. Bilateral adrenal infiltration in Erdheim-Chester disease. Report of seven cases and literature review. J Clin Endocrinol Metab. 2007;92:2007-12.
31. Opie KM, Kaye J, Vinciullo C. Erdheim-Chester disease. Australas J Dermatol. 2003;44:194-8.
32. Droupy S, Attias D, Eschwege P, et al. Bilateral hydronephrosis in a patient with Erdheim-Chester disease. J Urol. 1999;162:2084-5.
33. Arnaud L, Pierre I, Beigelman-Aubry C, et al. Pulmonary involvement in Erdheim-Chester disease: a single-center study of thirty-four patients and a review of the literature. Arthritis Rheum. 2010;62:3504-12.
34. Brun AL, Touitou-Gottenberg D, Haroche J, et al. Erdheim-Chester disease: CT findings of thoracic involvement. Eur Radiol. 2010;20:2579-87. A major radiologic thoracic review of 40 ECD patients describing infiltration into the mediastinal spaces including the pericardium, coronary sulci, and right atrium; association with pleural and interstitial lung diseases is frequently observed.
35. Lachenal F, Cotton F, Desmurs-Clavel H, et al. Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systematic review of the literature. J Neurol. 2006;253:1267-77.
36. Drier A, Haroche J, Savatovsky J, et al. Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings. Radiology. 2010;255:586-94.
37. Sheu SY, Wenzel RR, Kersting C, et al. Erdheim-Chester disease: case report with multisystemic manifestations including testes, thyroid, and lymph nodes, and a review of literature. J Clin Pathol. 2004;57:1225-8.
38. Provenzano E, Barter SJ, Wright PA, et al. Erdheim-chester disease presenting as bilateral clinically malignant breast masses. Am J Surg Pathol. 2010;34:584-8.
39. Johnson TR, Lenhard MS, Weidinger M, et al. An unusual breast tumor. Radiologe. 2009;49:942-5.
40. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harbouring the BRAF V600E mutation. Blood. 2013;121:1495-500. A major pilot study of three ECD patients with a proof of concept demonstration of the importance of BRAF inhibitors in BRAF mutated histiocytoses.
41. Myra C, Sloper L, Tighe PJ, et al. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol. 2004;88:844-7.
42. Boissel N, Wechsler B, Leblond V. Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation. Ann Intern Med. 2001;135:844-5.
43. Gaspar N, Boudou P, Haroche J, et al. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for adult histiocytic disorders with central nervous system involvement. Haematologica. 2006;91:1121-5.
44. Braiteh F, Boxrud C, Esmaeli B, et al. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood. 2005;106:2992-4.
45. Janku F, Amin HM, Yang D, et al. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol. 2010;28:e633-6.
46. Haroche J, Amoura Z, Charlotte F, et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood. 2008;111:5413-5.
47. Aouba A, Georgin-Lavialle S, Pagnoux C, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood. 2010;116:4070-6.
48. Dagna L, Corti A, Langheim S, et al. Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol. 2012;30:e286-90. A study focusing on the crucial importance of TNF alpha in ECD; two patients were treated with infliximab, with interesting results.
49. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol. 2005;23:6771-90.
50. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54.
51. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16.
52. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919-23.
53. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120:2700-3. An important study of a large number of histiocytic disorders with half of ECD and LCH patients tested mutated for BRAF V600E; no mutations found in all the other non-Langerhans histiocytosis tested (for example Rosai-Dorfman disease).
54. Emile JF, Charlotte F, Amoura Z, et al. BRAF mutations in Erdheim-Chester disease. J Clin Oncol. 2013;31:398.
55. Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366:2038-40.
56. Diamond EL, Abdel-Wahab O, Pentsova E, et al. Detection of an NRAS mutation in Erdheim-Chester disease. Blood. 2013;122:1089-91. An interesting study with detection of an NRAS mutation in an ECD case, focusing on the importance of the RAS-RAF-MEK-ERK pathway in this condition.
57. Stoppacciaro A, Ferrarini M, Salmaggi C, et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum. 2006;54:4018-22.
58. Dagna L, Girlanda S, Langheim S, et al. Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology (Oxford). 2010;49:1203-6.
59. Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood. 2011;117:2783-90. This important cytokine analysis from serum samples of 37 ECD patients reveals an intense systemic immune activation mainly involving IFNα, IL-1/IL1-RA, IL-6, IL-12, and MCP-1, emphasising the systemic immune Th-1-oriented perturbation associated with this condition.
60. Haroche J, Arnaud L, Cohen-Aubart F, Hervier B, Charlotte F, Emile JF, et al. Erdheim-Chester disease. Rheum Dis Clin N Am. 2013;39(2):299-311.